Article
Impact of PCSK9 inhibitors on bone disease: A comprehensive drug-target Mendelian randomization study
2025-03-11
Abstract excerpt
<h4>Background</h4> While certain studies suggest a relationship between hyperlipidemia and bone metabolism, the exact nature of proprotein convertase subtilisin/kexin 9 inhibitors (PCSK9i, targeted by, eg, alirocumab), which were originally developed for lowering LDL cholesterol inhibitors, with bone disease is still unclear. This research endeavors to uncover the potential causal relationship between PCSK9i and...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ef90027b-7c32-5311-96de-ad7d6aa1a35a
- DOI
- 10.1101/2025.03.09.25323603
